UPDATE 1-VeriChip shares jump after H1N1 patent license win

Sept 21 (Reuters) – Shares of VeriChip Corp (CHIP.O)

tripled after the company said it had been granted an exclusive

license to two patents, which will help it to develop

implantable virus detection systems in humans.

 The patents, held by VeriChip partner Receptors LLC, relate

to biosensors that can detect the H1N1 and other viruses, and

biological threats such as methicillin-resistant Staphylococcus

aureus, VeriChip said in a statement.

 The technology will combine with VeriChip's implantable

radio frequency identification devices to develop virus triage

detection systems.

 The triage system will provide multiple levels of

identification -- the first will identify the agent as virus or

non-virus, the second level will classify the virus and alert

the user to the presence of pandemic threat viruses and the

third level will identify the precise pathogen, VeriChip said

in a white paper published May 7, 2009.

 Shares of VeriChip were up 186 percent at $3.28 Monday late

afternoon trade on Nasdaq. They had touched a year high of

$3.43 earlier in the session.

 (Reporting by Mansi Dutta in Bangalore; Editing by Mike Miller

and Anil D'Silva)

 

 

http://www.reuters.com/article/rbssTechMediaTelecomNews/idUSBNG49295720090921

Popularity: 8% [?]